Risk of cardiometabolic diseases in patients with chronic parasitism Circulatory System
Conditions
Interventions
During Phase I, the population and the chief from the districts of Libreville and Koulamoutou from two provinces in Gabon, will be informed about the aim, the importance and the benefit of the study.
Sponsors
European & Developing Countries Clinical Trials Partnership
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age between 18-60 years 2. Residency in the city where the study will be conducted (since at least two years) 3. Consent form signed by the participant and the medical investigator at inclusion
Exclusion criteria
Exclusion criteria: 1. Patients 60years 2. Severe clinical event under investigation, that is life-threatening, uncontrolled 3. Refusal to participate in the study 4. Patient who should travel a long distance to the study site 5. History of coronary disease or stroke 6. Active/chronic viral hepatitis 7. HIV infection 8. Tuberculosis known patients 9. Fever or antimalarial drug intake within the last 2 months 10. Other antiparasitic treatment within the 6 months preceding the recruitment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency or incidence of CMD risk factors (defined as the presence of any of the following conditions: metabolic syndrome, high level of inflammatory and monocyte activation markers, High Framingham score) in parasitic-infected and non-infected individuals in urban versus rural areas (from patient records at months 36-39) | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using patient records: 1. Incidence of IPIs in urban and rural areas (months 24 – 27, and months 36-39) 2. Prevalence of new CMDRF in urban and rural areas at the end of the cohort study (months 36-39) 3. Evolution of Framingham score globally and according to the type of parasitism and study area (months 12-15; months 24-27, and months 36-39) 4. Evolution of the levels of inflammatory biomarkers in participants from urban and rural areas (months 12-15; months 24-27, and months 36-39) 5. Incidence of CMDRF, including metabolic syndrome, chronic inflammation, and high blood pressure in the general population and between groups. (months 36-39) | — |
Countries
Gabon
Outcome results
None listed